Drug intelligence / Profile preview

SNVG-34

Development stage: Preclinical
Lead developer: Immorta Bio
Modality: Cell Therapies

Overview

SNVG-34 is a cell therapy drug candidate initially developed by Immorta Bio. It is currently in preclinical development, with its primary therapeutic focus on neoplasms, specifically breast cancer, as well as skin and musculoskeletal diseases. Detailed information about its mechanism of action, specific cellular modality (e.g., CAR-T, TCR), or molecular targets has not been disclosed publicly. The drug has not yet entered clinical trials and remains in the early stages of research and development[1].

Other names: SNVG-34SNVG34SNVG 34

Beyond the preview

Go deeper on SNVG-34.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNVG-34.

Explore the full profile